Travere Therapeutics, Inc.
TVTX
Pozycja w akcjach
#3493
Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies... Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.
Cena akcji
$52.43
Ostatnia synchronizacja: 2026-10-20
Kapitalizacja rynkowa
$4.94B
Zmiana (1 dzień)
3.83%
Zmiana (1 rok)
88.58%
Kraj
US
Handel Travere Therapeutics, Inc. (TVTX)
Kategoria
Healthcare
Przychody dla Travere Therapeutics, Inc. (TVTX)
Przychody w Jun 2026 TTM: $591.33M
Według najnowszych raportów finansowych Travere Therapeutics, Inc., obecny przychód firmy (TTM) wynosi $591.33M. W roku 2023 firma osiągnęła przychód w wysokości $145.24M wzrost w porównaniu do przychodu z roku 2022, który wynosił $109.46M. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy Travere Therapeutics, Inc. od 2009 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $591.33M | 153.60% |
| 2024 | $233.18M | 60.55% |
| 2023 | $145.24M | 32.69% |
| 2022 | $109.46M | -16.97% |
| 2021 | $131.84M | -33.52% |
| 2020 | $198.32M | 13.11% |
| 2019 | $175.34M | 6.75% |
| 2018 | $164.25M | 6.01% |
| 2017 | $154.94M | 15.98% |
| 2016 | $133.59M | 33.74% |
| 2015 | $99.89M | 254.19% |
| 2014 | $28.20M | 0.00% |
| 2013 | 0.00 | 0.00% |
| 2012 | 0.00 | 0.00% |
| 2009 | 0.00 | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | 2,034.90% |
US
|
|
| $2.23B | 276.78% |
US
|
|
| $15.74B | 2,562.52% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 918.26% |
NL
|
